Abstract
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have